Log In
Print
BCIQ
Print
Print this Print this
 

Ragweed Allergy Immunotherapy Tablet (AIT) (Ragwitek) (MK-3641) (formerly SCH 039641)

  Manage Alerts
Collapse Summary General Information
Company ALK-Abello A/S
DescriptionTablet-based sublingual allergen immunotherapy
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityBiologic
Latest Stage of DevelopmentApproved
Standard IndicationAllergy
Indication DetailsTreat ragweed-induced allergic rhinitis; Treat ragweed-induced rhinoconjunctivitis
Regulatory Designation

U.S. - Undisclosed Review (Treat ragweed-induced allergic rhinitis);
Canada - Standard Review (Treat ragweed-induced allergic rhinitis)

Partner

Merck & Co. Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today